SeraCare and Toma Bio have developed a solid tumor gene analysis kit. — GenomeWeb
inShare SeraCare Launches Circulating Tumor DNA Reference Materials for NGS and Digital PCR-based Oncology Assays
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of two new circulating tumor DNA (ctDNA) products at the 2016 Molecular Medicine Tri-Conference in San Francisco.
NEW YORK (GenomeWeb) – SeraCare Life Sciences today announced a licensing agreement with the University of California, San Francisco for the use of its trisomy 21, 18, and 13 trophoblast cell line materials to develop reference materials for non-invasive prenatal testing of chromosomal abnormalities.
The new precision medicine business unit of SeraCare Life Sciences, Milford, Mass, has launched its first product, the Seraseq solid tumor mutation mix I.
The market leaders in the global legionella testing market are involved in continuous efforts for the development of innovative methodologies of testing which would increase the efficiency and accuracy of test results while providing the smooth processing of larger samples simultaneously.